Skip to main content

Table 5 EQ-5D-5L index score comparing 2 U-500R dosing algorithms in individuals with severely insulin-resistant type 2 diabetes

From: Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial

EQ-5D-5L US Index - Visit

U-500R

Treatment (n)

LSM (SE)

p-value Visit Comparison (Change from Baseline)a

LSM Difference (95 % CI) vs.

U-500R TID

Screening

TID (161)

0.77 (0.01)

0.97

0.01 (−0.02, 0.04)

BID (158)

0.78 (0.01)

0.35

Baseline

TID (162)

 

0.00 (−0.03, 0.03)

BID (161)

 

Endpoint

TID (159)

−0.02 (0.01)

0.30

0.01 (−0.02, 0.03)

BID (152)

−0.01 (0.01)

0.80

  1. Abbreviations: BID twice daily; CI confidence interval; LSM least-square mean; SE standard error; TID thrice daily; U-500R human regular U-500 insulin
  2. a p-values and 95 % CI of difference of LSM of change from baseline were from the MMRM model